Universal TNF-Alpha Assay for Small Sample Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring TNF alpha inhibitor drugs and their antibodies in biological samples are cumbersome, not universally applicable, and lack accuracy and reproducibility, particularly for small blood samples, posing challenges in clinical management and patient-specific treatment.
Innovation Solution
A method using labeled TNF-alpha conjugates that form molecular complexes with TNF-alpha inhibitor drugs, generating a detectable signal, allowing for the quantification of both drugs and antibodies in small blood samples, with the option to add a TNF-alpha inhibitor-binding agent to enhance assay performance, and a spiking assay to validate measurements.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional monitoring methods are used for TNF alpha inhibitor drugs and antibodies, then the assay can detect the presence of drugs and antibodies, but the methods are cumbersome and lack accuracy and reproducibility
Solution Approach 1:
The assay is divided into distinct functional modules: TNF-alpha conjugate preparation, sample incubation, signal generation, and detection. Each module performs a specific function (binding, complex formation, signal amplification), allowing the complex overall process to be managed through standardized, reproducible steps while maintaining high measurement precision through controlled conditions at each stage
Solution Approach 2:
The TNF-alpha conjugate system serves multiple functions: it acts as both the capture agent for drugs and antibodies, and as the platform for signal generation. The same conjugate structure can detect different TNF-alpha inhibitors and their corresponding antibodies, providing a universal assay platform that improves reproducibility while maintaining accuracy across multiple analytes
2Adaptability or versatility
If conventional methods are used for monitoring TNF alpha inhibitor drugs, then detection is possible, but the methods are not universally applicable to different drugs and antibodies
Solution Approach 1:
The TNF-alpha conjugate serves as a universal recognition element that can bind to multiple different TNF-alpha inhibitors (infliximab, etanercept, adalimumab, certolizumab pegol, golimumab) and their corresponding antibodies. This single conjugate platform provides universal applicability across the entire class of TNF-alpha inhibitors while maintaining accurate quantification through standardized signal generation and detection protocols
Solution Approach 2:
The assay accommodates different TNF-alpha inhibitors and antibodies by adjusting parameters such as incubation time, conjugate concentration, and signal detection settings, while maintaining the core assay architecture. This allows universal applicability across different drugs without compromising measurement precision through optimized conditions for each analyte
3Measurement precision
If conventional monitoring methods are used, then the assay can process biological samples, but the methods lack sensitivity for small blood samples
Solution Approach 1:
The TNF-alpha conjugate acts as an intermediary that amplifies the detection signal by forming large molecular complexes with the drugs and antibodies. This complex formation concentrates the analytes and enhances the detectable signal, allowing sensitive detection in small blood samples where conventional methods would lack sufficient sensitivity
Solution Approach 2:
The TNF-alpha conjugate creates composite molecular structures by combining TNF-alpha protein with drug molecules and antibodies in a single detectable complex. This composite formation increases the effective size and detectability of the analytes, enabling sensitive measurement in limited sample volumes through enhanced signal generation from the composite structure
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides sensitive, accurate, and reproducible measurements of TNF-alpha inhibitor drugs and antibodies in small blood samples, enabling universal application and improved clinical management by identifying neutralizing antibodies and optimizing treatment regimens.
Implementation Method 1
A method using labeled TNF-alpha conjugates that form molecular complexes with TNF-alpha inhibitor drugs, generating a detectable signal
Implementation Method 2
providing a first TNF-α conjugate comprising TNF-α and a first conjugated moiety, providing a second TNF-α conjugate comprising TNF-α and a second conjugated moiety, said second moiety being capable of generating or ameliorating a detectable signal in the presence of a molecular complex comprising a TNF-α inhibitor, the first TNF-α conjugate and the second TNF-α conjugate
Data Source
AI summary
The present invention relates to a kit of parts and methods for determining the presence and quantity of one or more TNF-α inhibitor drugs and/or anti-TNF-α inhibitor drug antibodies in one or more biological samples each comprising less than 200 μl, the method comprising the steps of providing a reaction liquid comprising the sample, a first TNF-α conjugate comprising TNF-α and a first conjugated moiety and a second TNF-α conjugate comprising TNF-α and a second conjugated moiety, said second moiety being capable of generating or ameliorating a detectable signal in the presence of a molecular complex comprising a TNF-α inhibitor, followed by detecting the change in signal when the complex between the TNF-α inhibitor drug, the first TNF-α conjugate and a the second TNF-α conjugate forms.